QIAGEN powered by

LabCorp uses QCI

and HGMD to improve identification and interpretation of genetic variants within inherited diseases.

Press Releases

Qiagen Launches 'Digital Partner' Program

QIAGEN has launched a "Digital Insights Partnership" program designed to expand the market for its bioinformatics products through various third-party collaborations and deals

QIAGEN and Illumina Partner

The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems

1 million patients analyzed

QCI, a clinical decision support platform for interpretation and reporting of variants derived from analysis of next-generation sequencing (NGS) data, has achieved a milestone of more than 1 million patient test cases analyzed and interpreted

Global Initiative to combat antimicrobial resistance

A new initiative to help address the global crisis of antibiotic-resistant pathogens. ...

Japan’s new molecular oncology initiative

Japan’s Center for Cancer Genomics and Advanced Therapeutics (C-CAT), a unit within the National Cancer Center (NCC) of Japan, ...

NHS extends use of HGMD

Genomics England have extended the contract for QIAGEN’s HGMD® Human Gene Mutation Database offering on behalf of the NHS in England.